Compare ASPN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPN | ADCT |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | Switzerland |
| Employees | 854 | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.5M | 445.2M |
| IPO Year | 2011 | 2019 |
| Metric | ASPN | ADCT |
|---|---|---|
| Price | $5.36 | $3.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.25 | ★ $7.75 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $271,103,000.00 | $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $50.03 | $66.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $2.30 | $1.83 |
| 52 Week High | $9.78 | $4.98 |
| Indicator | ASPN | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 67.31 | 28.02 |
| Support Level | $3.01 | $3.11 |
| Resistance Level | $7.46 | $4.73 |
| Average True Range (ATR) | 0.43 | 0.22 |
| MACD | 0.13 | -0.06 |
| Stochastic Oscillator | 72.50 | 3.00 |
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).